

1/21





FIG. 1

2/21



^a Indolent lymphoma includes follicular and marginal zone lymphoma.

^b Treatment cycles are 4 weeks. Rituximab is given weekly at Weeks 2-4 in Cycle 1 only. Up to 6 cycles of rituximab will be given.

^c Level 3 Hu5F9-G4 dosing regimen consists of 1 mg/kg priming dose on Day 1, then a loading dose of either 20 or 30 mg/kg twice weekly x 1 week, followed by weekly maintenance doses of 20 or 30 mg/kg. Dose concentration to be determined by the CTSC

^d Simon two-stage minimax design with an alpha of 0.1 and a power of 0.80. H0=null hypothesis; H1=alternative hypothesis.

^e 1, 10 mg/kg represents a first priming dose of 1 mg/kg followed by a maintenance dose of 10 mg/kg of Hu5F9-G4 one week after, similarly for 1, 20 mg/kg.

FIG. 2

3/21




FIG. 3

4/21

Variables	Effect size on odds for response	P value
CD19 cell count at baseline	5 times increase is associated with 2 time increase	0.0021
% CD19 over lymphocytes at baseline	5 times increase is associated with 1.9 time increase in the odds	0.0026
Months from the last anti-CD20 therapy	2 times increase is associated with 1.9 time increase in the odds	0.007
Rituximab concentration in subject at baseline	5 times increase is associated with 1.6 time increase in the odds	0.0014

Other variables evaluated: Hemoglobin, neutrophils, platelets, ECOG status, time from last therapy, LDH, albumin

FIG. 4

5/21




FIG. 5

6/21




FIG. 6

7/21




FIG. 7

8/21

Best overall response	Unselected data (N=42)	CD19+ B Cell Positive Patients (N=28)
Objective Response Rate (ORR)	14 (33%)	14 (50%)
Complete Response (CR)	6 (14%)	6 (21%)
Partial Response (PR)	8 (19%)	8 (29%)
Stable Disease (SD)	5 (12%)	3 (11%)
Progressive Disease (PD)	23 (55%)	11 (39%)

FIG. 8

9/21




FIG. 9

10/21

Best overall response	Unselected data (N=42)	CD20+ B-Cell Positive Patients (N=16)
Objective Response Rate (ORR)	14 (33%)	10 (62.5%)
Complete Response (CR)	6 (14%)	4 (25%)
Partial Response (PR)	8 (19%)	6 (37.5%)

FIG. 10

11/21




FIG. 11A




FIG. 11B

12/21




FIG. 12A




FIG. 12B

13/21




FIG. 13

14/21




FIG. 14A




FIG. 14B

15/21




FIG. 15A




FIG. 15B

16/21





FIG. 16

17/21



18/21




FIG. 18

19/21




FIG. 19




FIG. 20

21/21

FIG. 21A


Peripheral blood
trough RO

FIG. 21B

Bone marrow
trough RO